Heart failure & cardiomyopathies
Estimating the Clinical and Budgetary Impact of Using Angiotensin Receptor Neprilysin Inhibitor as First Line Therapy in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF)
Authors' conclusion
Increasing the proportion of patients receiving ARNI instead of angiotensin converting enzyme inhibitors as first-line treatment of HFrEF will lead to a considerable number of additional life years gained and prevented hospitalizations but with additional cost in terms of health care expenditure in Sweden and in the United Kingdom.
Study context
- Population
- Patients with HFrEF in Sweden and the UK
- Comparison
- Increased angiotensin receptor neprilysin inhibitor (ARNI) use vs conservative ARNI prescription as first-line therapy
- Outcome
- Clinical and budgetary outcomes (life years gained, hospitalizations prevented, costs)
- Follow-up
- 10 years
Methodological details10-year time horizon, annual incident cohorts
- 10-year time horizon
- Annual incident cohorts
Main finding
As reported in the abstract
Sweden
Life years gained with increased ARNI use (Sweden)
about 7000-12 300
Hospitalizations prevented (Sweden)
2600-4600
Additional cost (Sweden)
112-195 million euros
Further findings
UK
- Similar results to Sweden, on a larger population
Original publication
Estimating the Clinical and Budgetary Impact of Using Angiotensin Receptor Neprilysin Inhibitor as First Line Therapy in Patients with HFrEF. ESC Heart Fail. Published 26 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →